Drug Eluting Stents und Antikoagulation in der perioperativen Phase – Eine interdisziplinäre Aufgabe

Zusammenfassung

Bei koronararteriellen Interventionen kardialer Risikopatienten werden zunehmend Drug Eluting Stents implantiert. Diese Stents machen eine verlängerte Antikoagulation bis zu einem Jahr oder länger erforderlich. Plättchenaggregatiosnhemmer wie Clopidogrel und Acetylsalicylsäure sollten daher, wenn möglich, in der perioperativen Phase kontinuierlich appliziert werden. Eine Unterbrechung der Plättchenaggregationshemmung sollte bei jedem Patienten individuell nur nach interdisziplinärer Absprache zwischen Chrirugen, Kardiologen und Anästhesisten erfolgen.

Summary

Drug eluting stents are nowadays more frequently used in cardiac risk patients undergoing coronary artery interventions. These stents make prolonged anticoagulation up to one year or longer necessary to avoid acute stent thrombosis. Anti–platelet drugs like clopidogrel and aspirin should therefore be continued perioperatively if possible. Decission to stop anti–plateletts should be made for each individual patient only after interdisciplinary discussion with the cardiologist, surgeon and anaesthesiologist.

Drug Eluting Stent - Bare Metal Stent - Koronare Herzerkrankung - Plättchenaggregationshemmung - Clopidogrel - Aspirin

Drug Eluting Stent - Bare Metal Stent - coronary artery disease - anti–platelet therapy - clopidogrel - aspirin

Kernaussagen

• Vor einer Stent–Implantation sollte der Kardiologe die Notwendigkeit einer dualen PAH und deren Dauer von mindestens 12 Monaten bei DES mit dem Patienten besprechen.

• Patienten, die nach einer PCI innerhalb eines Jahres einem operativen oder interventionellem Eingriff unterzogen werden sollen, sollten keinen DES erhalten.

• Patienten müssen ausführlich und mit Nachdruck auf die Notwendigkeit der dualen PAH hingewiesen werden.

• Patienten sollten eindeutige Informationen über die Art des implantierten Stents erhalten.

• Patienten sollten dahingehend geschult werden, dass sie nur nach Rücksprache mit dem behandelnden Kardiologen die PAH unterbrechen.

• Ärzte aller Fachgebiete, die invasive oder operative Eingriffe durchführen, müssen für die potenziell katastrophalen Folgen einer PAH–Unterbrechung sensibilisiert werden. Bei Unklarheiten bezüglich der PAH sollte die optimale perioperative Therapie mit dem Kardiologen besprochen werden, der den Patienten behandelt.

Literatur

• 1 Daemen J, Serruys PW.. Drug–Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug–Eluting Stents: Meaningful Advances or More of the Same?.  Circulation. 2007;  116 316-328
• 2 Curfman GD.. Sirolimus–Eluting Coronary Stents.  The New England Journal of Medicine. 2002;  346 1770-1771
• 3 Smith EJ, Rothman MT.. Antiproliferative coatings for the treatment of coronary heart disease:. what are the targets and which are the tools?.  J Interv Cardiol. 2003;  16 475-483
• 4 Stone GW, Moses JW, Ellis SG. et al. . Safety and Efficacy of Sirolimus– and Paclitaxel–Eluting Coronary Stents.  The New England Journal of Medicine. 2007;  356 998-1008
• 5 Spaulding C, Daemen J, Boersma E. et al. . A Pooled Analysis of Data Comparing Sirolimus–Eluting Stents with Bare–Metal Stents.  The New England Journal of Medicine. 2007;  356 989-997
• 6 Kastrati A, Mehilli J, Pache J. et al. . Analysis of 14 Trials Comparing Sirolimus–Eluting Stents with Bare–Metal Stents.  The New England Journal of Medicine. 2007;  356 1030-1039
• 7 Mauri L, Hsieh Wh, Massaro JM. et al. . Stent Thrombosis in Randomized Clinical Trials of Drug–Eluting Stents.  The New England Journal of Medicine. 2007;  356 1020-1029
• 8 Serruys PW, de P Jaegere, Kiemeneij F. et al. . A Comparison of Balloon–Expandable–Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease.  The New England Journal of Medicine. 1994;  331 489-495
• 9 Leon MB, Baim DS, Popma JJ. et al. . A Clinical Trial Comparing Three Antithrombotic–Drug Regimens after Coronary–Artery Stenting.  The New England Journal of Medicine. 1998;  339 1665-1671
• 10 Wilson SH, Rihal CS, Bell MR. et al. . Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin.  The American Journal of Cardiology. 1999;  83 1006-1011
• 11 Grines CL, Bonow RO, Casey DEJ. et al. . Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents: A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians.  Circulation. 2007;  115 813-818
• 12 Marroquin OC, Selzer F, Mulukutla SR. et al. . A Comparison of Bare–Metal and Drug–Eluting Stents for Off–Label Indications.  The New England Journal of Medicine. 2008;  358 342-352
• 13 Moreno R, Fernandez C, Calvo L. et al. . Meta–Analysis Comparing the Effect of Drug–Eluting Versus Bare Metal Stents on Risk of Acute Myocardial Infarction During Follow–Up.  The American Journal of Cardiology. 2007;  99 621-625
• 14 Fleisher LA, Beckman JA, Brown KA. et al. . ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.  Circulation. 2007;  116
• 15 Posner KL, Van GA Norman, Chan V.. Adverse Cardiac Outcomes After Noncardiac Surgery in Patients with Prior Percutaneous Transluminal Coronary Angioplasty.  Anesthesia Analgesia. 1999;  89 553-560
• 16 Kaluza GL, Joseph J, Lee JR. et al. . Catastrophic outcomes of noncardiac surgery soon after coronary stenting.  Journal of the American College of Cardiology. 2000;  35 1288-1294
• 17 Schouten O, van Domburg RT, Bax JJ. et al. . Noncardiac Surgery After Coronary Stenting: Early Surgery and Interruption of Antiplatelet Therapy Are Associated With an Increase in Major Adverse Cardiac Events.  Journal of the American College of Cardiology. 2007;  49 122-124
• 18 Godet G, Le Y Manach, Lesache F. et al. . Drug–eluting stent thrombosis in patients undergoing non–cardiac surgery: is it always a problem?.  Br J Anaesth. 2008;  100
• 19 Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: A special risk for late stent thrombosis.  Journal of the American College of Cardiology. 2005;  45 456-459
• 20 Ong ATL, McFadden EP, Regar E. et al. . Late Angiographic Stent Thrombosis (LAST) Events With Drug–Eluting Stents.  Journal of the American College of Cardiology. 2005;  45 2088-2092
• 21 Iakovou I, Schmidt T, Bonizzoni E. et al. . Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug–Eluting Stents.  JAMA: The Journal of the American Medical Association. 2005;  293 2126-2130
• 22 Spertus JA, Kettelkamp R, Vance C. et al. . Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug–Eluting Stent Placement: Results From the PREMIER Registry.  Circulation. 2006;  113 2803-2809
• 23 Vicenzi MN, Meislitzer T, Heitzinger B. et al. . Coronary artery stenting and non–cardiac surgery–a prospective outcome study.  British Journal of Anaesthesia. 2006;  96 686-693
• 24 Yusuf S, Zhao F, Mehta SR. et al. . Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST–Segment Elevation.  N Engl J Med. 2001;  345 494-502
• 25 Eikelboom JW, Hirsh J.. Bleeding and management of bleeding.  European Heart Journal Supplements. 2006;  8
• 26 Ferraris VA, Swanson E.. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations.  Surg Gynecol Obstet. 1983;  156 439-442
• 27 Merritt JC, Bhatt DL.. The efficacy and safety of perioperative antiplatelet therapy.  J Thromb Thrombolysis. 2004;  17 21-27
• 28 Burger W, Chemnitius JM, Kneissl GD, Rücker G.. Low–dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta–analysis.  J Intern Med. 2005;  257 399-414
• 29 Compton PA, Zankar AA, Adesanya AO. et al. . Risk of Noncardiac Surgery After Coronary Drug–Eluting Stent Implantation.  The American Journal of Cardiology. 2006;  98 1212-1213
• 30 Cannon CP, Mehta SR, Aranki SF.. Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery.  The Annals of Thoracic Surgery. 2005;  80 768-779
• 31 McFadden EP, Stabile E, Regar E. et al. . Late thrombosis in drug–eluting coronary stents after discontinuation of antiplatelet therapy.  The Lancet. 2004;  364 1519-1521
• 32 Nasser M, Kapeliovich M, Markiewicz W.. Late thrombosis of sirolimus–eluting stents following noncardiac surgery.  Catheter Cardiovasc Interv. 2005;  65 516-519
• 33 Webster SE, Payne DA, Jones CI. et al. . Anti–platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy.  Journal of Vascular Surgery. 2004;  40 463-468
• 34 Greenbaum AB, Ohman EM, Gibson CM. et al. . Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced–dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP–AMI) angiographic trial.  American Heart Journal. 2007;  154 702-709